Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Increase in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 2,100,000 shares, an increase of 44.8% from the November 30th total of 1,450,000 shares. Currently, 2.5% of the shares of the company are sold short. Based on an average daily trading volume, of 481,300 shares, the days-to-cover ratio is presently 4.4 days.

Analysts Set New Price Targets

CMPX has been the topic of several analyst reports. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, November 11th. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Monday, September 16th. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, D. Boral Capital initiated coverage on shares of Compass Therapeutics in a research note on Monday, December 23rd. They issued a “buy” rating and a $32.00 target price for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Price Performance

Shares of CMPX stock traded down $0.02 on Monday, hitting $1.45. 64,858 shares of the company’s stock were exchanged, compared to its average volume of 435,385. The stock has a market cap of $198.82 million, a P/E ratio of -3.91 and a beta of 0.89. The company has a 50 day moving average of $1.60 and a 200 day moving average of $1.42. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Sell-side analysts predict that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Hedge funds have recently bought and sold shares of the business. Rovin Capital UT ADV bought a new stake in shares of Compass Therapeutics during the 3rd quarter worth $25,000. Intech Investment Management LLC bought a new stake in Compass Therapeutics in the 3rd quarter worth approximately $30,000. XTX Topco Ltd purchased a new position in shares of Compass Therapeutics in the third quarter worth about $37,000. Cubist Systematic Strategies LLC purchased a new position in shares of Compass Therapeutics in the second quarter worth $41,000. Finally, Panagora Asset Management Inc. purchased a new stake in Compass Therapeutics in the 2nd quarter worth approximately $68,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.